Introduction {#section5-1756286419855485}
============

Imaging techniques such as high-resolution nerve ultrasound (HRUS) and corneal confocal microscopy (CCM) have recently provided a novel insight in our understanding of the dynamic nature of peripheral nerve morphology.

HRUS studies have confirmed the multifocal cross-sectional area (CSA) enlargement in distal and proximal segments of almost all peripheral nerves and brachial plexus in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP); additionally, some pattern analyses of the focal or diffuse swelling of peripheral nerves have been attempted.^[@bibr1-1756286419855485][@bibr2-1756286419855485][@bibr3-1756286419855485][@bibr4-1756286419855485][@bibr5-1756286419855485][@bibr6-1756286419855485][@bibr7-1756286419855485][@bibr8-1756286419855485]--[@bibr9-1756286419855485]^ The distribution and extent of CSA increase seem not only to differentiate acute from chronic demyelinating diseases but also to distinguish between chronic autoimmune neuropathies themselves.^[@bibr10-1756286419855485][@bibr11-1756286419855485]--[@bibr12-1756286419855485]^

On the other hand, CCM, a rapidly developing, noninvasive technique, focuses on corneal imaging both in terms of inflammation and axonal loss. Its use has extended to a variety of neuropathies, mainly in diabetic neuropathy^[@bibr13-1756286419855485]^ but also in uncommon neuropathies.^[@bibr14-1756286419855485][@bibr15-1756286419855485]--[@bibr16-1756286419855485]^ The aspect of inflammation is depicted by a specific type of autochthonous immune cells, which had been identified as Langerhans cells.^[@bibr17-1756286419855485]^ The two existing studies on CCM in CIDP have shown a reduction in corneal nerve fiber parameters and an increase in corneal immune cell infiltrates in patients with CIDP compared with healthy controls.^[@bibr18-1756286419855485],[@bibr19-1756286419855485]^ However, the practical role of these parameters in clinical routine remains unclear. The primary objective of this prospective pilot study was to systematically investigate the potential of CCM and HRUS parameters as neuroimaging markers of disease progression in a cohort of patients with CIDP during individualized treatment based on the clinician's decision.

Materials and methods {#section6-1756286419855485}
=====================

Study protocol: clinical assessment {#section7-1756286419855485}
-----------------------------------

A cohort of patients with CIDP were recruited during the last trimester of 2015 at the Departments of Neurology, St. Josef and Bergmannsheil University Hospital, Bochum, Germany. The diagnosis of CIDP was based on the respective criteria of the Peripheral Nerve Society/European Federation of Neurological Societies.^[@bibr20-1756286419855485]^ The study was approved by the local ethics committee (Ethics Committee University of Ruhr University Bochum, Nr 4905-14). All patients gave their written informed consent prior to the inclusion into the study. The study was performed in accordance with the Declaration of Helsinki.

The patients with CIDP underwent clinical, sonographical and electrophysiological evaluation as well as CCM three times during a period of 18 months in a mean time of 8.9 ± 1.2 months between visits (visits 1, 2 and 3). Motor dysfunction was quantified by two examiners (AL and ALF) using the inflammatory neuropathy cause and treatment (INCAT) validated overall disability sum score (ODSS) as described previously.^[@bibr21-1756286419855485]^ For the evaluation of the longitudinal data, the patients were divided retrospectively to two groups depending on the INCAT/ODSS. Patients were consid-ered clinically stable when the INCAT/ODSS remained unchanged or improved over the period of 18 months; all remaining patients were considered progressive. Details of the clinical course and the individual symptoms were assessed on the basis of information from the clinical records. A total of two patients in the cohort were diagnosed with diabetes mellitus type II (HbA1c % \<7 for both of them). HRUS, CCM as well as clinical examination were performed by different examiners and all examiners were blinded to these groups during the study.

Nerve conduction studies {#section8-1756286419855485}
------------------------

All electrophysiological assessments included standard nerve conduction studies (NCSs) of sensory and motor nerves of the lower and upper limbs of the most affected side. All NCSs were performed by a board-certified neurologist (MSY) with the use of a Medtronic 4 channel electromyography Device (Medtronic, Meerbusch, Germany) as described before.^[@bibr22-1756286419855485],[@bibr23-1756286419855485]^ Motor studies were performed in the tibial nerve and sensory studies in the sural nerve bilaterally. The reference values used were those proposed by Stöhr and colleagues.^[@bibr24-1756286419855485]^

Ultrasound examination {#section9-1756286419855485}
----------------------

For the ultrasound studies, we used an AplioXG ultrasound system (Toshiba Medical, Tochigi, Japan). For superficial nerves (median, ulnar, radial, brachial plexus, tibial at the ankle, and sural) we used an 18-MHz linear array transducer, and for the deeper nerves (tibial and fibular in the popliteal fossa) a 12-MHz linear array transducer. The measurements were performed by one examiner (KP) as described before.^[@bibr22-1756286419855485],[@bibr23-1756286419855485],[@bibr25-1756286419855485],[@bibr26-1756286419855485]^

The peripheral nerves were measured bilaterally at the following sites: median nerve at the entrance to carpal tunnel (flexor retinaculum), forearm (15 cm proximal to flexor retinaculum), upper arm (midpoint between medial epicondyle and axillary fossa), ulnar nerve at the Guyon canal, forearm (15 cm proximal to the Guyon canal), elbow (between medial epicondyle and olecranon), upper arm (midpoint between medial epicondyle and axillary fossa), radial nerve in the spiral groove, tibial nerve in the popliteal fossa and at the ankle, fibular nerve at the fibular head and in the popliteal fossa and sural nerve (between the lateral and medial heads of the gastrocnemius muscle).

For each of the nerves of both sides of all patients, the intra-nerve and inter-nerve CSA variabilities were calculated according to the following: 'intra-nerve cross-sectional area variability' (for each nerve) as maximal cross-sectional area/minimal cross-sectional area, 'inter-nerve cross-sectional area variability' (for each patient) as maximal intra-nerve cross-sectional area variability/minimal intra-nerve cross-sectional area variability. Furthermore, Bochum ultrasound score (BUS) was calculated for each patient and each visit, summarizing the CSA of: (1) the ulnar nerve in the Guyons' canal, (2) the ulnar nerve in the upper arm, (3) the radial nerve in the spiral groove, and (4) the sural nerve between the gastrocnemius muscle (maximum score of 4 if CSA in every one of the four locations is increased). Bilateral CSA increase was counted only once.^[@bibr23-1756286419855485]^ The examiner was blinded for the clinical outcome.

Corneal confocal microscopy {#section10-1756286419855485}
---------------------------

All study participants were scanned by two examiners (DS and TG) using a Heidelberg Retinal Tomograph III with a Rostock Cornea Module (HRT III RCM) (Heidelberg Engineering GmbH, Heidelberg, Germany) as previously described.^[@bibr13-1756286419855485]^ Five high-quality images of one eye were analyzed and the mean of these results was calculated. A fully automated software was used to quantify corneal nerve fiber density (CNFD; nerves/mm^2^), corneal nerve branch density (CNBD; branches/mm^2^), and corneal nerve fiber length (CNFL; mm/mm^2^) (ACCMetrics version 2.0; M.A. Dabbah, Imaging Science and Biomedical Engineering, Manchester, UK). Cell infiltrates were analyzed manually by DS in the same images that were also used to quantify corneal nerves. The total cell number of cells per mm^2^ was calculated. These assessments were standardized for the area analyzed. Both examiners were blinded for the clinical outcome.

Skin punch biopsy and quantitative sensory testing {#section11-1756286419855485}
--------------------------------------------------

For assessment of intra-epidermal nerve fiber density skin punch biopsy was obtained during the first follow-up visit (V2) from the distal lower leg (10 cm above the lateral malleolus) and from the proximal thigh as recommended by the European Federation of Neurological Societies/Peripheral Nerve Society,^[@bibr27-1756286419855485]^ done by two examiners (DS and EEK). Skin samples were processed as previously described.^[@bibr28-1756286419855485]^ The intra-epidermal nerve fiber density per mm (IEFND) was quantified manually by EEK. The reference IEFND values of our department are \>15 fibers/mm for the proximal thigh, and \>9 fibers/mm for the distal lower leg, which were adopted from the lab of Prof. Sommer and Prof. Üceyler, Würzburg, Germany. Quan-titative sensory testing (QST) was conducted at the dorsal feet according to the standardized protocol of the German Research Network on Neuropathic Pain (DFNS) and data were analyzed as described before.^[@bibr29-1756286419855485],[@bibr30-1756286419855485]^ QST was done by LE, data analysis was performed by NK.

Statistics {#section12-1756286419855485}
----------

The analysis was performed by KP using Prism 7 (GraphPad Software, La Jolla, CA, USA). All data are presented as mean ± standard deviation (SD). D'Agostino and Pearson normality tests were applied to test the distribution of the groups and the differences were assessed using two-sample Student's *t* tests. \**p* \< 0.05 was regarded as statistically significant. The Pearson correlation coefficient *r* was calculated for all correlation analyses. We applied the nonlinear Spearman's rank correlation coefficient *rs* for correlations with ODSS and with F-wave latency. For the correlations, the maximum F-wave latency was used for absent F-waves. Due to the large number of sonographic and electrophysiological measurements, a Bonferroni correction was performed, so that only *p* \< 0.001 values were accepted as statistically significant.

Results {#section13-1756286419855485}
=======

Baseline clinical data for all patients {#section14-1756286419855485}
---------------------------------------

A total of 17 patients with CIDP (mean age 62.0 years, SD ± 8.7; 7 women) underwent clinical, sonographical and electrophysiological evaluation as well as CCM at a mean of 8.8 years (SD ± 5.6 years) after disease onset (visit 1) as well as during the next 18 months in a mean time of 8.9 ± 1.2 months between visits (visits 2 and 3) ([Table 1](#table1-1756286419855485){ref-type="table"}). The patients showed a mean ODSS/INCAT of 3.7 (SD ± 1.4, min--max 1--5) at visit 1. During the study period, all patients were treated with 1 g/kg intravenous immunoglobulins every 4--6 weeks whereas six of them received additional oral immunosuppression (azathioprine or mycophenolate mofetil).

###### 

Patients characteristics at baseline.

![](10.1177_1756286419855485-table1)

  --------------------------------------------------------------------------------------------
                                        Patients with CIDP   Stable            Progressive
  ------------------------------------- -------------------- ----------------- ---------------
  **Age (years ± SD)**                  62.0 ± 8.7           59.7 ± 8.3        63.6 ± 9

  **Sex (% female)**                    41.1% (*n* = 7)      57.1% (*n* = 4)   30% (*n* = 3)

  **Years from first manifestation**\   8.8 ± 5.6            7.2 ± 4.6         9.9 ± 6.2
  (mean ± SD)                                                                  

  **Years from first diagnosis**\       8.1 ± 4.9            6.6 ± 3.1         9.2 ± 5.8
  (mean ± SD)                                                                  

  **Immunosuppression**                 *n* = 6              *n* = 2           *n* = 4

  **ODSS (mean ± SD)**                  3.7 ± 1.4            3.2 ± 1.3         3.8 ± 1.3
  --------------------------------------------------------------------------------------------

CIDP, chronic inflammatory demyelinating polyradiculoneuropathy; ODSS, overall disability score scale; SD, standard deviation.

Baseline NCS and HRUS data for all patients {#section15-1756286419855485}
-------------------------------------------

NCS at baseline (V1) showed a typical sensorimotor demyelinating polyneuropathy. A total of 6 patients showed a distal tibial compound motor action potential (CMAP) over 3 mV whereas 15 patients showed a median CMAP over 4 mV at baseline ([Supplementary Table 1](https://journals.sagepub.com/doi/suppl/10.1177/1756286419855485)).

The BUS was ⩾2 for 12 patients at baseline (mean CSA values and intra-nerve/inter-nerve variability values are presented in [Supplementary Table 2](https://journals.sagepub.com/doi/suppl/10.1177/1756286419855485)). The HRUS values of any of the nerves at baseline did not correlate with disease duration or INCAT/ODSS disability score.

Baseline CCM data for all patients {#section16-1756286419855485}
----------------------------------

CCM showed a mean CNFD ± SD of 27.4 ± 8.8/mm^2^, a mean CNBD of 39.3 ± 26.4/mm^2^, a mean CNFL of 15.9 ± 5.1 mm/mm^2^ and a mean number of 49 ± 59.6 total cells/mm^2^. We found no correlation of the CCM parameters for disease duration or INCAT/ODSS ([Figure 1](#fig1-1756286419855485){ref-type="fig"}) but the two patients with the highest number of total cells at baseline belonged to the groups with lowest disease duration (2 and 3 years) and the highest ODSS (ODSS 5 for both of them). There was no correlation between total cell number and corneal nerve fiber length or density.

![Corneal confocal microscopy data at baseline (visit 1): Total corneal cells infiltrates, CNFD, CNBD and CNFL values are depicted in relation to disease duration and ODSS/INCAT score at baseline. No statistical significant correlation of these parameters was found.\
CNBD, corneal nerve branch density; CNFD, corneal nerve fiber density; CNFL, corneal nerve fiber length; INCAT, inflammatory neuropathy cause and treatment; ODSS, overall disability score scale.](10.1177_1756286419855485-fig1){#fig1-1756286419855485}

QST and IEFND data for all patients {#section17-1756286419855485}
-----------------------------------

QST was performed at the first follow-up visit (V2) in 15 patients with CIDP and detected abnormally decreased *z*-values for cold detection threshold (−2.3 ± 1.1), for mechanical detection threshold (−2.1 ± 2.1) and vibration detection threshold (−3 ± 2), indicating a mixed sensory loss of detection. Hypoesthesia to cold stimuli, vibration or mechanical stimuli was evident in 67%, 73% and 53%, respectively. 53% of the patients reported paradoxical heat sensation as a sign for central disinhibition within the corresponding central pathways of the small fibers. All assessed pain thresholds (cold, heat, mechanical stimuli and pressure pain thresholds) were within the normal range.

Skin biopsy was assessed in 13 patients with CIDP (V2) and IEFND was reduced for all of them as an indication of small fiber nerve affection (IEFND, mean ± SD, lower leg: 2.9 ± 3 fibers/mm, upper leg 4.7 ± 4.8 fibers/mm). IEFND and CCM parameters did not correlate. Of the 13 patients with signs of small fiber nerve affection, 10 received membrane stabilizing substances in the context of neuropathic pain.

Longitudinal studies: markers of clinical progression {#section18-1756286419855485}
-----------------------------------------------------

Epidemiological data on stable (*n* = 7) and progressive (*n* = 10) patients with CIDP are presented in [Table 1](#table1-1756286419855485){ref-type="table"}. Age, sex and ODSS/INCAT did not differ significantly between both groups, whereas patients with a progressive disease showed a slightly increased disease duration (stable 7.2 ± 4.6 *versus* progressive 9.9 ± 6.2 years from first disease manifestation, n.s.). Furthermore, from the six patients receiving oral immunosuppression two remained clinically stable, whereas four patients presented with a disease progression. The mean values of the NCS did not differ significantly between patients with stable disease and disease progression (see [Supplementary Tables 3](https://journals.sagepub.com/doi/suppl/10.1177/1756286419855485) and [4](https://journals.sagepub.com/doi/suppl/10.1177/1756286419855485)).

Regarding the clinical phenotype and previous disease course of the stable patients (*n* = 7) one of them was characterized by an acute sensorimotor disease onset but improved and remained stable until the beginning of our current study, all other stable patients were characterized by a typical sensory onset of the symptoms and a further sensorimotor progression, two of them still received immunosuppression due to course of the disease in the previous years. In the group of progressive patients, four of them received immunosuppression due to aggressive disease course ([Table 1](#table1-1756286419855485){ref-type="table"}).

Patients with clinical progression included the following ODSS/INCAT increase (raw data, number of patients: ODSS at the beginning of the study → at the end of the study): 2 patients: 4 → 6, 1 patient: 2 → 4, 3 patients: 5 → 6, 1 patient: 1 → 2, 1 patient: 2 → 3, 1 patient: 3 → 4, 1 patient: 4 → 5.

Longitudinal HRUS data: CSA and CSA variability measures {#section19-1756286419855485}
--------------------------------------------------------

The mean CSA values for the patients with stable and progressive disease are presented in [Supplementary Tables 5](https://journals.sagepub.com/doi/suppl/10.1177/1756286419855485) and [6](https://journals.sagepub.com/doi/suppl/10.1177/1756286419855485).

Patients with progressive disease during the study period had the following sonographical characteristics:

CSA mean values of the median nerve at forearm, of the radial nerve at the spiral groove, of the fibular nerve at fibular head and of the sural nerve between the lateral and medial head of gastrocnemius muscle were above reference values at V1 and remained abnormal during the whole study period. This was not the case for patients with stable disease as these mean values improved over this period.

These results were confirmed in the evaluation of the different nerve segments. A total of 260 segments (bilaterally) were evaluated in each visit for the progressive and 182 for the stable CIDP group. For the progressive group at visit 1, visit 2 and visit 3 44%, 47% and 55% of these segments had increased CSA values mostly at the above-mentioned locations. For the stable CIDP group these values were lower and decreased over time (40%, 47% and 34% for visit 1, 2 and 3 respectively).

As some of these segments are included in the BUS, we evaluated its use in the longitudinal CIDP evaluation for the first time.

BUS increased or remained stable at a maximum of 4 points for 8 (true positive -- 2 false negative) of the 10 patients in the progressive CIDP group and for 1 patient (false positive -- 7 true negative) in the stable disease group. Therefore, a BUS increase from V1 to V3 or BUS of 4 points at V1 predicted with a sensitivity of 80% (8/2 + 8), specificity 87.5% (7/1 + 7), a positive predictive value (PPV) of 88% (8/1 + 8) and a negative predictive value (NPV) of 77% (7/2 + 7) a disease progression in our cohort. Representative HRUS pictures of the BUS for a stable and a progressive patient are presented in [Figure 2](#fig2-1756286419855485){ref-type="fig"}.

![Representative ultrasound pictures of the nerves evaluated for the BUS for a stable and a progressive patient at the beginning of the study (ulnar nerve in Guyon's canal and upper arm, radial and sural nerve). The stable patient has a BUS of 1 \[only ulnar nerve in Guyon's canal shows an increased CSA of 9 mm^2^ (normal values of our laboratory \<7.22 mm^2^) whereas the progressive patient has a BUS of 3 (increased CSA of the ulnar nerve in upper arm (\<10.17 mm^2^), of the radial nerve (\<6.2 mm^2^) and of the sural nerve (\<3.01 mm^2^)\].\
BUS, Bochum ultrasound score; CSA, cross-sectional area.](10.1177_1756286419855485-fig2){#fig2-1756286419855485}

Furthermore, all mean values of intra-nerve CSA variability as well as the mean inter-nerve CSA variability increased over time. Stable patients did not show this homogenous increase of variability measures but fluctuations with an improvement for the majority of the values at V3 ([Supplementary Tables 3](https://journals.sagepub.com/doi/suppl/10.1177/1756286419855485) and [4](https://journals.sagepub.com/doi/suppl/10.1177/1756286419855485)). These results were confirmed after evaluating the individual nerves with increased CSA variability. For the stable group, 56 nerves were evaluated and among them 32% had increased intra-nerve variability at V1 and 35% at V3 (increase of 3%). The progressive CIDP group showed 26% of the nerves with an increased CSA variability at V1 and 41% at V3 (increase of 15%).

Longitudinal CCM parameters of inflammation and degeneration {#section20-1756286419855485}
------------------------------------------------------------

Total cell count as a marker of inflammation revealed significantly increased corneal cell infiltrates for patients in the progressive group compared with patients in the group with stable disease (mean total cell count stable CIDP 13 ± 11, progressive CIDP 74.8 ± 63.7, \**p* = 0.02). All patients with progressive disease over the next 18 months presented with more than 30 total cells/mm^2^ in the cornea at baseline (sensitivity, specificity, PPV, NPV for clinical progression of 100% in our cohort; [Figures 3](#fig3-1756286419855485){ref-type="fig"} and [4](#fig4-1756286419855485){ref-type="fig"}). Total corneal cell values correlated neither with ODSS score nor with NCS or HRUS parameters at any of the visits. During the study period, inflammatory cell infiltrates in the cornea remained high for progressive patients and low for patients with stable CIDP disease ([Table 2](#table2-1756286419855485){ref-type="table"}).

![Total corneal cell infiltrates at baseline (Visit 1, V1): Patients with progressive disease (ODSS/INCAT increase of ⩾1) showed already at baseline higher inflammatory infiltrates compared with patients with stable CIDP, \**p* \< 0.05. Using a cut-off value of 30 total cells/mm^2^ (dotted line) all patients with progressive disease show higher values (sensitivity, specificity for clinical progression 100%).\
CIDP, chronic inflammatory demyelinating polyradiculoneuropathy; INCAT, inflammatory neuropathy cause and treatment; ODSS, overall disability score scale.](10.1177_1756286419855485-fig3){#fig3-1756286419855485}

![Representative pictures of corneal confocal microscopy. (a): patient with CIDP (stable), (b): patient with CIDP (progressive), (c): healthy control.\
CIDP, chronic inflammatory demyelinating polyradiculoneuropathy.](10.1177_1756286419855485-fig4){#fig4-1756286419855485}

###### 

Findings of the corneal confocal microscopy for the patients with stable CIDP (***n* =** 7) and patients with progressive CIDP (*n* = 10). Total cells at V1 were significantly higher for patients with progressive CIDP (*p* = 0.0237).

![](10.1177_1756286419855485-table2)

  Stable        Visit 1    Visit 2    Visit 3                 
  ------------- ---------- ---------- --------- ------ ------ ------
  CNFD          27.9       6.9        22.9      6.4    25.2   2.1
  CNBD          36.4       10.8       24.3      12.2   26.2   8.4
  CNFL          15.6       2.0        12.3      2.7    14.0   1.2
  total cells   **13.0**   **11.1**   16.8      12.2   17.5   16.3
  Progressive   Visit 1    Visit 2    Visit 3                 
                Mean       SD         Mean      SD     Mean   SD
  CNFD          27.1       10.3       24.4      9.6    24.0   7.6
  CNBD          41.4       33.9       48.7      27.1   41.4   25.5
  CNFL          16.0       6.6        15.5      4.4    15.1   4.7
  total cells   **74.8**   **63.7**   72.6      75.4   61.4   65.1

Total cells at V1 were significantly higher for patients with progressive CIDP (*p* = 0.0237).

CNBD, corneal nerve branch density; CNFD, corneal nerve fiber density; CNFL, corneal nerve fiber length; SD, standard deviation.

On the other hand, corneal nerve parameters did not differ significantly between the two groups and remained unchanged during 18 months ([Table 2](#table2-1756286419855485){ref-type="table"}). Furthermore, the subgroups of stable (*n* = 6) and progressive CIDP (*n* = 9) displayed similar somatosensory profiles at baseline, with the exception of less sensory loss in the progressive group in the assessment of cold and vibration detection threshold and heat pain threshold (QST data, [Supplementary Table 7](https://journals.sagepub.com/doi/suppl/10.1177/1756286419855485)).

Discussion {#section21-1756286419855485}
==========

To summarize, in our CIDP cohort corneal cell infiltration at baseline assessed by CCM was related to further clinical progression, and increase in BUS assessed using HRUS correlated positively with disease activity.

In terms of HRUS, the majority of patients with a BUS increase over the period of 18 months or a high BUS score at baseline were identified as patients with a disease progression. BUS has been previously proposed from our group as a marker to distinguish between CIDP and acute inflammatory neuropathies (AIDP) with a sensitivity and specificity of 90%.^[@bibr6-1756286419855485],[@bibr9-1756286419855485],[@bibr22-1756286419855485]^ Its main advantages are easy applicability in daily routine by clinical neurologists as it includes only four nerve segments bilaterally.

In a previous pilot study with 11 patients with CIDP,^[@bibr26-1756286419855485]^ the CSA variability increased parallel to clinical deterioration. However, the patients in that study were evaluated on average 8.5 ± 3.2 days (range: 2--45 days) after symptom onset, in contrast to the present cohort of chronic disease stages (on average 8.8 ± 5.6 years after disease onset). Intra-nerve CSA variability of all nerves seems to increase parallel to ODSS/INCAT deterioration at this later stage. The echogenicity of peripheral nerves was not evaluated in the present study. This aspect represents a challenge for future HRUS studies.^[@bibr6-1756286419855485],[@bibr31-1756286419855485]^

An increase of total corneal cell infiltrates has been described in two cross-sectional CIDP studies.^[@bibr18-1756286419855485],[@bibr19-1756286419855485]^ In the current study total cell infiltrates with more than 30/mm^2^ at baseline identified all patients with a clinical progression in the next 18 months, showing the potential of this parameter to predict disease progression for the first time. These findings suggest residual inflammatory infiltrates in patients with progressive disease, which are visible in CCM, but probably also present in peripheral nerves thus leading to the clinical deterioration. Interestingly, the inflammatory infiltrates in the cornea remained increased until the end of the study, which poses the question whether they would improve after further treatment escalation.

In contrast with previous CCM studies, we could not confirm the correlation of corneal cell infiltrates and degeneration markers with disease duration and ODSS/INCAT at baseline. However, our cohort was smaller than the one reported before (*n* = 88). Still, the previously reported increased dendritic cells in contact with axons for patients with higher INCAT scores points to the same direction as our current study.^[@bibr19-1756286419855485]^

Including two patients with diabetes may have influenced the results of the NCSs. However, it has been shown that there is no relevant CSA increase in the nerves composing the BUS.^[@bibr32-1756286419855485]^ Furthermore, a corneal cell infiltration in context to diabetes mellitus has only been reported in a rodent model (but not in humans) with a different methodical approach.^[@bibr33-1756286419855485]^

Compared with published normative data, corneal nerve parameters did not achieve abnormal values in our study (with one exception) and showed only a slight decrease within the studied period.[@bibr34-1756286419855485] This may be not only related to a progression of a disease. Other factors, like age, also influence the corneal nerves and may explain the changes.^[@bibr35-1756286419855485]^ Furthermore, the corneal sub-basal plexus has been evaluated longer than 12 months only in a few cases and mainly in diabetic neuropathy.^[@bibr36-1756286419855485]^

In contrast with that, we found a severe histological affection of small fibers in the skin with reduced IENFD and sensory impairment, similar to previous studies.[@bibr37-1756286419855485][@bibr38-1756286419855485]--[@bibr39-1756286419855485] The mismatch between the CCM nerve parameters and the sensory and morphological findings in the skin might reflect different pathophysiological mechanisms of small fiber damage in different organs (cornea, skin) similarly to findings in diabetic neuropathy.^[@bibr40-1756286419855485]^

To our knowledge, this is the first study to characterize the somatosensory profile in CIDP. In our cohort with longer lasting CIDP duration the sensory abnormalities corresponded to the cluster of deafferentation, which also dominated a previously published larger cohort of polyneuropathy of various origin, and might reflect the advanced stage of the disease.^[@bibr41-1756286419855485],[@bibr42-1756286419855485]^ In contrast with corneal cells, neither intra-epidermal nerve fiber density nor nerve parameters in CCM or QST parameters were suitable as a marker of disease progression in our group.

Surely, the present pilot study has some major limitations. We performed a single-center, prospective data analysis with a small number of patients representing every day clinical practice using a variety of imaging studies. CIDP treatment was heterogenous as it was adapted by the treating neurologist individually, based on the clinical course of the disease and NCS and therefore intravenous immunoglobulins did not correspond to the concentration of 1 g/kg every 3 weeks reported by the IGIV-C CIDP Efficacy study as an optimal treatment protocol.^[@bibr42-1756286419855485],[@bibr43-1756286419855485]^ However, as concluded from Dalakas and colleagues, protocols of immunoglobulin treatment vary in every day practice as the clinical presentation and treatment response differ between patients.^[@bibr44-1756286419855485]^ The purpose of the present study was indeed to prove whether novel HRUS and CCM markers are able to predict clinical stability in the context of this heterogenous disease. Further larger multicenter studies, including patients at earlier disease stages, are needed to confirm our results.

In conclusion, the reported novel neuroimaging biomarkers (corneal cell infiltrates in CCM and BUS in HRUS) have the potential to predict clinical disease course and aid the clinical decision towards treatment escalation or de-escalation for patients with CIDP.

Supplemental Material {#section22-1756286419855485}
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